Hypha Labs, Tryptomics enter phase II of mushroom tech partnership

LAS VEGAS - Hypha Labs, Inc. (OTCQB:FUNI), a micro-cap biotech company with a current market value of $3.41 million, announced Wednesday the launch of Phase II in its strategic partnership with Tryptomics to develop proprietary varieties of bioreactor-optimized mushroom species.

The collaboration combines Hypha’s patented Mushroom Accelerator platform with Tryptomics’ On-Site Science Services and Metabolomics Pipeline to advance research and development of functional mushroom technologies.

According to the announcement, Phase II will implement in-house analytical testing capabilities and third-party verification of Hypha’s internal results through Certificate of Analysis verification. The partnership also includes the deployment of duplicate Mushroom Accelerator systems for synchronized experimentation.

The companies aim to achieve rapid production of bioavailable "Micro-Pearls" in eight days, which they claim will provide faster iteration and scalability. The first new bioreactor-optimized strains are scheduled to launch in 2026.

"This strategic partnership aligns Hypha Labs’ proprietary cultivation technology with Tryptomics’ Metabolomics Pipeline to provide scalable and quality assured mushroom supplements to society," said Caleb King, Chief Science Officer and Cofounder of Tryptomics.

Craig Ellins, Chief Science Officer at Hypha Labs, stated, "Tryptomics brings the most diverse skillset under one roof and this sets us up to lead the next wave of biotech wellness."

Hypha Labs is currently conducting a Regulation A+ public offering for investors interested in the company’s expansion from consumer-focused devices to large-scale ingredient production.

The information in this article is based on a press release statement from Hypha Labs, Inc.

In other recent news, Hypha Labs, Inc. has announced an agreement with Automated Technical Services to design and build a commercial-scale Mushroom Accelerator. This development marks a significant step for Hypha Labs as it aims to expand its production capabilities. The new system will produce the company’s proprietary mushroom-based ingredients on a larger scale for sale to nutraceutical manufacturers around the world. The technology compresses the production of functional mushroom compounds from months to just eight days. This advancement represents a move from Hypha Labs’ current countertop units to a more extensive production system. The company’s efforts in scaling up production could potentially enhance its market reach and operational efficiency. These recent developments reflect Hypha Labs’ commitment to innovation and growth in the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.